Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

First patient dosed in the phase I/II trial of KB-103

May 11, 2018

FDA approves IND for female hair loss trial of Histogen's HSC-660

May 7, 2018

Lilly initiates phase III study of mirikizumab in moderate to severe plaque psoriasis

May 7, 2018

Azitra raises new financing to advance pipeline

May 4, 2018

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

May 3, 2018

Exicure reports phase I data on AST-005 in plaque psoriasis

May 2, 2018

AbbVie submits European MAA for risankizumab in moderate to severe plaque psoriasis

May 2, 2018

EMA committee hands down positive opinion for Cimzia in moderate to severe plaque psoriasis

April 30, 2018

AbbVie submits BLA to the FDA for risankizumab in moderate to severe plaque psoriasis

April 26, 2018

KB-103 receives orphan medicinal product designation in Europe

April 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...